Cargando…

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Recent discoveries suggest that the critical events leading to the anti-proliferative activity of the IMiD immunomodulatory agents lenalidomide and pomalidomide in multiple myeloma (MM) cells are initiated by Cereblon-dependent ubiquitination and proteasomal degradation of substrate proteins Ikaros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bjorklund, C C, Lu, L, Kang, J, Hagner, P R, Havens, C G, Amatangelo, M, Wang, M, Ren, Y, Couto, S, Breider, M, Ning, Y, Gandhi, A K, Daniel, T O, Chopra, R, Klippel, A, Thakurta, A G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635186/ https://www.ncbi.nlm.nih.gov/pubmed/26430725 http://dx.doi.org/10.1038/bcj.2015.66

Ejemplares similares

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4(CRBN) Protein Degradation Axis
por: Yang, Seung-Joo, et al.
Publicado: (2021)

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
por: Hagner, Patrick R., et al.
Publicado: (2022)

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
por: Shimizu, Nobuyuki, et al.
Publicado: (2021)

CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
por: Barankiewicz, Joanna, et al.
Publicado: (2022)

Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus
por: Rivellese, Felice, et al.
Publicado: (2021)

Genetic Mapping and Allelic Loss Analysis in Mouse Thymic Lymphomas of Helios and Aiolos Belonging to the Ikaros Gene Family
por: Xu, Hongbin, et al.
Publicado: (2001)

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase
por: An, Jian, et al.
Publicado: (2017)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide
por: Tateno, Shumpei, et al.
Publicado: (2020)

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus
por: Schafer, Peter H, et al.
Publicado: (2018)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
por: Thakurta, A, et al.
Publicado: (2014)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Aiolos regulates eosinophil migration into tissues
por: Felton, Jennifer M., et al.
Publicado: (2021)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Aiolos and Lymphocyte Mimicry in Lung Cancer
por: Terada, Lance S, et al.
Publicado: (2014)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

IKZF3/Aiolos Is Associated with but Not Sufficient for the Expression of IL-10 by CD4(+) T Cells
por: Ridley, Michael L., et al.
Publicado: (2020)

AIOLOS Variants Causing Immunodeficiency in Human and Mice
por: Yamashita, Motoi, et al.
Publicado: (2022)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
por: Lopez-Millan, Belen, et al.
Publicado: (2017)

Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide
por: Davis, David A., et al.
Publicado: (2017)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4
por: Belair, David G., et al.
Publicado: (2020)

Comparative Genomics Identifies Putative Interspecies Mechanisms Underlying Crbn-Sall4-Linked Thalidomide Embryopathy
por: Kowalski, Thayne Woycinck, et al.
Publicado: (2021)

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019)

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
por: Jones, J. R., et al.
Publicado: (2021)

Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4
por: Campos Carrascosa, Lucia, et al.
Publicado: (2017)

CRBN is downregulated in lung cancer and negatively regulates TLR2, 4 and 7 stimulation in lung cancer cells
por: Kim, Mi‐Jeong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_avm7rt7eo7pchh3kt24e48375i